Project Grant R01HL172029
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$742K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This Project Grant award of $108,030, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine if neutrophils produced through emergency granulopoiesis, a reactive process that increases neutrophil production during immune challenges like myocardial infarction (MI), exhibit altered functions that contribute to the pathogenesis of heart failure after MI. The key objectives are 1) to assess...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $654,530 to the University of Utah to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (cMet HFPEF). The 4-year project aims to determine how cardiac-specific SGK1 signaling, particularly through its phosphorylation of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of cardiomyocyte glutamine synthesis in heart failure development, fibroblast activation, and cardiac metabolism. The $772,808 award to Temple University, with a project period from December 2024 to November 2028, will support research to determine if targeting cardiomyocyte glutamine synthesis can reduce the progression of heart...
The National Heart Lung and Blood Institute (NHLBI) awarded a $989,908 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Board of Regents of Nevada System of Higher Education, doing business as the University of Nevada, Las Vegas (UNLV). The 4-year grant, effective January 1, 2025, aims to improve the efficacy of cell-based cardiac repair by examining whether treating mesenchymal stem cells (MSCs) with recombinant Wnt11 (Rwnt11) can enhance their ability to repair...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $634,183 to Loyola University of Chicago to research new mechanisms of cardiac ryanodine receptor (RyR) dysfunction during oxidative stress. The key goals are to: 1) define the molecular mechanisms by which intersubunit cross-linking of RyR activates the channel and disrupts calcium homeostasis during oxidative stress, and 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...